Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Pharming Group N.V.
Industry Sector: HealthTechnology
CEO: Fabrice Chouraqui, MBA
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: -51.95
Exchange/Ticker 1: Euronext Amsterdam:PHARM
Exchange/Ticker 2: N/A
Latest Market Cap: $587,098,299
BioCentury | Jan 22, 2025
Management Tracks
Fabrice Chouraqui to become CEO of Pharming
Plus: Woodcock, Kim join Friends of Cancer Research’s board and updates from Recursion, Medtronic and more
BioCentury | Dec 12, 2024
Data Byte
Candel leads biotech gainers amid wave of data readouts
Prostate cancer data lead to a nearly 70% stock bump; dermatitis data sink Q32 shares
BioCentury | Nov 20, 2024
Product Development
Biotechs now match pharma for FDA approvals
Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves
BioCentury | Jul 18, 2023
Management Tracks
Gosebruch named CEO of Neumora
Plus: Petti becomes CEO at Leucid Bio, and updates from Acelyrin, Larimar, Pharming and more
BioCentury | Mar 24, 2023
Finance
March 24 Quick Takes: FDA approves Pharming’s immunodeficiency therapy
Plus: Incyte’s setback, 89bio’s upsized follow-on, EU pharma legislation, and updates from Novo and Brii
BioCentury | Mar 2, 2023
Data Byte
At least nine PDUFA dates on deck in March
Decisions include leniolisib and trofinetide, both of which could be the first drugs approved for their indications
BioCentury | Sep 29, 2022
Finance
Sept. 28 Quick Takes: TYK2 play Sudo emerges with $37M
Plus: Priority review for Pharming and updates from TCR2, Moderna and more
BioCentury | Feb 3, 2022
Product Development
Feb. 2 Quick Takes: Pharming plans global submissions for leniolisib
Plus Novo ends Staten deal, new Pfizer vaccine data coming, Novartis scuttles pan-JAK and more
BioCentury | Jun 21, 2021
Management Tracks
WuXi vet Yao joins Allogene Overland as CEO; plus uniQure, Merck, Exelixis and Pharming
Allogene Overland Biopharm, a joint venture between Overland Pharmaceuticals and Allogene Therapeutics Inc. (NASDAQ:ALLO) focused on bringing allogeneic cell therapies to China, named
BioCentury | Mar 13, 2021
Product Development
Long COVID therapies are starting to populate a sparse pipeline
Candidate treatments are split between therapies addressing symptoms versus hypothesized drivers
Items per page:
1 - 10 of 275